← All trials
NCT01015547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2003
- Primary completion
- Nov 1, 2007
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of HelsinkiLead sponsor
- Rheumatism Foundation HospitalCollaborator
- University of HelsinkiStudy director
- Foundation for Paediatric Research, FinlandCollaborator
- Scandinavian Rheumatology Research FoundationCollaborator
- Paijat-Hame Hospital DistrictCollaborator
- University of HelsinkiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.